Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Q2 2026 earnings

Reported July 30, 2026 · Before market open

Revenue$796.2MBeat by $28.0M
EPS$0.30Beat by $0.08
Revenue estimate$768.2M
EPS estimate$0.22
“Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio,”
Management

Next report

Oct 29, 2026 (in a month)
Revenue estimate$812.9M
EPS estimate$0.23

Financials

Q2 2026

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation & ratios

Valuation

as of 09/16/26
See full
Market cap$5.8B+89.6%
Enterprise value$8.24B+59.6%
P/E36.9×-870×
P/S1.9×+0.8×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Debt / equity77.8×—
Current ratio2.2×+0.8×

Segments

By product

See full
Subtotal dosage forms$482.3M+11.8%
Oral solid$175.2M-1.7%
Subtotal therapeutic classes$149.3M+17.1%
Central nervous system$95.3M+14.3%
Distribution$86.9M-12.8%

By segment

See full
Affordable Medicines$489.9M—
AvKARE$157.0M-3.7%

FAQ

When did Amneal Pharmaceuticals, Inc. report Q2 2026 earnings?
Amneal Pharmaceuticals, Inc. (AMRX) reported Q2 2026 earnings on July 30, 2026 before market open.
What were Amneal Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
Amneal Pharmaceuticals, Inc. reported revenue of $796.2M and eps of $0.30 for Q2 2026.
Did Amneal Pharmaceuticals, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $768.2M by $28.0M. EPS beat the consensus estimate of $0.22 by $0.08.
How did Amneal Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.9% from $724.5M a year earlier and eps grew 20.0% from $0.25.
Where can I find Amneal Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001723128-26-000025) and the 10-Q periodic report (0001723128-26-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.